Review ArticlesAdvances in Diagnostic Immunohistochemistry for Primary Tumors of the Central Nervous SystemMeredith, David M. MD, PhDAuthor Information Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA The author has no funding or conflicts of interest to disclose. Reprints: David M. Meredith, MD, PhD, Department of Pathology, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115 (e-mail: email@example.com). Advances In Anatomic Pathology: May 2020 - Volume 27 - Issue 3 - p 206-219 doi: 10.1097/PAP.0000000000000225 Buy Metrics Abstract As genomic characterization becomes increasingly necessary for accurate diagnosis of tumors of the central nervous system, identification of rapidly assessible biomarkers is equally important to avoid excessive cost and delay in initiation of therapy. This article reviews novel immunohistochemical markers that may be used to determine mutation status, activation of signaling pathways, druggable targets, and cell lineage in many diverse tumor types. In particular, recently added entities to the 2016 WHO classification of central nervous system tumors will be addressed, including IDH-mutant gliomas, diffuse midline glioma, epithelioid glioblastoma, angiocentric glioma, RELA-rearranged ependymoma, embryonal tumors (medulloblastoma, atypical teratoid/rhabdoid tumor, pineoblastoma, embryonal tumor with multilayered rosettes, and other genetically defined high-grade neuroepithelial tumors), and meningiomas associated with germline alterations. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.